Clinical efficacy and safety of anticholinergic therapies in pediatric patients

References

• Centres for Disease Control and PreventionNational Health Interview Survey, US children2015 Available from: https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2015_SHS_Table_C-1.pdfAccessed August 31, 2017
   Google Scholar
• Asthma UKAsthma facts and statistics2017 Available from: https://www.asthma.org.uk/about/media/facts-and-statistics/Accessed August 26, 2017
   Google Scholar
• AsherMIKeilUAndersonHRInternational Study of Asthma and Allergies in Childhood (ISAAC): rationale and methodsEur Respir J1995834834917789502
   PubMed Web of Science ®Google Scholar
• EllwoodPAsherMIBeasleyRClaytonTOStewartAWISAAC Steering CommitteeThe international study of asthma and allergies in childhood (ISAAC): phase three rationale and methodsInt J Tuberc Lung Dis200591101615675544
   PubMed Web of Science ®Google Scholar
• MallolJCraneJvon MutiusEOdhiamboJKeilUStewartAISAAC Phase Three Study GroupThe International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesisAllergol Immunopathol (Madr)2013412738522771150
   PubMed Web of Science ®Google Scholar
• AsherIPearceNGlobal burden of asthma among childrenInt J Tuberc Lung Dis2014181269127825299857
   PubMed Web of Science ®Google Scholar
• The Global Asthma NetworkThe Global Asthma Report 2014 Available from: http://www.globalasthmareport.org/resources/Global_Asthma_Report_2014.pdfAccessed August 26, 2017
   Google Scholar
• MurrayCJVosTLozanoRDisability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592197222323245608
   PubMed Web of Science ®Google Scholar
• SchmierJKManjunathRHalpernMTJonesMLThompsonKDietteGBThe impact of inadequately controlled asthma in urban children on quality of life and productivityAnn Allergy Asthma Immunol200798324525117378255
   PubMed Web of Science ®Google Scholar
• MurrayCSPolettiGKebadzeTStudy of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in childrenThorax2006611537638216384881
   PubMed Web of Science ®Google Scholar
• GuttmannAZagorskiBAustinPCEffectiveness of emergency department asthma management strategies on return visits in children: a population-based studyPediatrics20071206e1402e141018055658
   PubMed Web of Science ®Google Scholar
• PedersenSEHurdSSLemanskeRFJrGlobal Initiative for AsthmaGlobal strategy for the diagnosis and management of asthma in children 5 years and youngerPediatr Pulmonol201146111720963782
   PubMed Web of Science ®Google Scholar
• Global Initiative for AsthmaGINA Report, Global strategy for asthma management and prevention2018 Available from: http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/Accessed March 25, 2018
   Google Scholar
• PriceDFromerLKaplanAvan der MolenTRomán-RodríguezMIs there a rationale and role for long-acting anticholinergic bronchodilators in asthma?NPJ Prim Care Respir Med2014241402325030457
   PubMed Web of Science ®Google Scholar
• McIvorERMcIvorRAThe evolving role of tiotropium in asthmaJ Asthma Allergy20171023123628860828
   PubMed Web of Science ®Google Scholar
• PhilipJThe effects of inhaled corticosteroids on growth in childrenOpen Respir Med J20148667325674176
   PubMedGoogle Scholar
• BarnesPJNeural mechanisms in asthmaBr Med Bull19924811491681352167
   PubMed Web of Science ®Google Scholar
• QureshiFZaritskyALakkisHEfficacy of nebulized ipratropium in severely asthmatic childrenAnn Emerg Med19972922052119018183
   PubMed Web of Science ®Google Scholar
• GriffithsBDucharmeFMCombined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in childrenCochrane Database Syst Rev20138CD000060
   PubMed Web of Science ®Google Scholar
• SchuhSJohnsonDWCallahanSCannyGLevisonHEfficacy of frequent nebulized ipratropium bromide added to frequent high-dose albuterol therapy in severe childhood asthmaJ Pediatr199512646396457699549
   PubMed Web of Science ®Google Scholar
• ZorcJJPusicMVOgbornCJLebetRDugganAKIpratropium bromide added to asthma treatment in the pediatric emergency departmentPediatrics19991034 Pt 174875210103297
   PubMed Web of Science ®Google Scholar
• TeohLCatesCJHurwitzMAcworthJPvan AsperenPChangABAnticholinergic therapy for acute asthma in childrenCochrane Database Syst Rev20124CD003797
   Google Scholar
• BarnesPJMuscarinic receptor subtypes in airwaysEur Respir J199363283318472820
   PubMed Web of Science ®Google Scholar
• GosensRZaagsmaJMeursHHalaykoAJMuscarinic receptor signaling in the pathophysiology of asthma and COPDRespir Res200677316684353
   PubMed Web of Science ®Google Scholar
• BusseWWDahlRJenkinsCCruzAALong-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?Eur Respir Rev201625139546426929422
   PubMed Web of Science ®Google Scholar
• BelmonteKECholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary diseaseProc Am Thorac Soc200524297304 discussion 311–31216267352
   PubMedGoogle Scholar
• AalbersRParkHSPositioning of long-acting muscarinic antagonists in the management of asthmaAllergy Asthma Immunol Res20179538639328677351
   PubMed Web of Science ®Google Scholar
• BarnesPJThe pharmacological properties of tiotropiumChest20001172 Suppl63S66S10673478
   PubMed Web of Science ®Google Scholar
• KerstjensHAEngelMDahlRTiotropium in asthma poorly controlled with standard combination therapyN Engl J Med2012367131198120722938706
   PubMed Web of Science ®Google Scholar
• KerstjensHACasaleTBBleeckerERTiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trialsLancet Respir Med20153536737625682232
   PubMed Web of Science ®Google Scholar
• OhtaKIchinoseMTohdaYLong-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled studyPLoS One2015104e012410925894430
   PubMed Web of Science ®Google Scholar
• PaggiaroPHalpinDMBuhlRThe effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trialJ Allergy Clin Immunol Pract201641104.e2113.e226563670
   PubMed Web of Science ®Google Scholar
• RaissyHHKellyHWTiotropium bromide in children and adolescents with asthmaPaediatr Drugs201719653353828808948
   PubMed Web of Science ®Google Scholar
• VogelbergCEngelMMoroni-ZentgrafPTiotropium in asth matic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging studyRespir Med201410891268127625081651
   PubMed Web of Science ®Google Scholar
• VogelbergCMoroni-ZentgrafPLeonaviciute-KlimantavicieneMA randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroidsRespir Res2015162025851298
   PubMed Web of Science ®Google Scholar
• HamelmannEVogelbergCVoelkerBTiotropium add-on therapy improves lung function in children and adolescents with moderate and severe symptomatic asthma, independent of markers of allergic statusAllergy201772S103:413
   Web of Science ®Google Scholar
• HamelmannEBatemanEDVogelbergCTiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trialJ Allergy Clin Immunol2016138244145026960245
   PubMed Web of Science ®Google Scholar
• VogelbergCEngelMLakiITiotropium add-on therapy improves lung function in children with symptomatic moderate asthmaJ Allergy Clin Immunol Pract20186621602162.e929751157
   PubMed Web of Science ®Google Scholar
• SzeflerSJMurphyKHarperT3rdA phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthmaJ Allergy Clin Immunol201714051277128728189771
   PubMed Web of Science ®Google Scholar
• BisgaardHVandewalkerMGrahamLMSafety of tiotropium in pre-school children with symptomatic persistent asthmaEur Respir J201648Suppl 60PA315
   Google Scholar
• HamelmannEBernsteinJAVandewalkerMA randomised controlled trial of tiotropium in adolescents with severe symptomatic asthmaEur Respir J2017491 pii: 1601100
   PubMed Web of Science ®Google Scholar
• VogelbergCEngelMLakiITiotropium add-on therapy improves lung function in children with symptomatic moderate asthmaJ Allergy Clin Immunol Pract2018
   PubMed Web of Science ®Google Scholar
• VrijlandtEJLEEl AzziGVandewalkerMSafety and efficacy of tiotropium in children aged 1–5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trialLancet Respir Med20186212713729361462
   PubMed Web of Science ®Google Scholar
• VogelbergCHamelmannESzeflerSOnce-daily tiotropium respimat add-on therapy improves lung function and control in adolescents and children with moderate symptomatic asthmaJ Allergy Clin Immunol20171392AB95
   Web of Science ®Google Scholar
• RodrigoGJNeffenHEfficacy and safety of tiotropium in school-age children with moderate–to-severe symptomatic asthma: a systematic reviewPediatr Allergy Immunol201728657357828692145
   PubMed Web of Science ®Google Scholar
• SchatzMRosenwasserLThe allergic asthma phenotypeJ Allergy Clin Immunol Pract201426645648 quiz 64925439351
   PubMed Web of Science ®Google Scholar
• HolgateSTBousquetJChungKFGroup for the Respect of Ethics and Excellence in Science: Asthma sectionSummary of recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthmaRespir Med200498647948715191031
   PubMed Web of Science ®Google Scholar
• VandewalkerMVogelbergCHamelmannETiotropium Respimat® add-on therapy improves lung function in adolescents and children with moderate symptomatic asthma, irrespective of IgE levels and eosinophil countPoster P521 presented at: the American Thoracic Society International ConferenceMay 19–24; 2016Washington, DC
   Google Scholar
• GoldsteinSVogelbergCHamelmannETiotropium Respimat® add-on therapy is effective in children and adolescents with severe symptomatic asthma, irrespective of immunoglobulin E levels and eosinophil countPoster P520 presented at: the American Thoracic Society International ConferenceMay 19–24; 2016Washington, DC
   Google Scholar
• BeehKMKirstenAMDusserDPharmacodynamics and pharmacokinetics following once-daily and twice-daily dosing of tiotropium Respimat® in asthma using standardized sample-contamination avoidanceJ Aerosol Med Pulm Drug Deliv201629540641526859538
   PubMed Web of Science ®Google Scholar
• SharmaAKerstjensHAAalbersRMoroni-ZentgrafPWeberBDahlRPharmacokinetics of tiotropium administered by Respimat((R)) in asthma patients: analysis of pooled data from Phase II and III clinical trialsPulm Pharmacol Ther201742253228039077
   PubMed Web of Science ®Google Scholar
• SharmaAWeiseSSzeflerSPharmacokinetics of tiotropium in patients aged 6–11 years with moderate asthma following administration via the Respimat® inhalerAbstract presented at EAACI PAAM Eur Acad Allergy Clin Immunol CongOctober 26–28, 2017London, UK
   Google Scholar
• SharmaAAalbersRHamelmannEPharmacokinetics of tiotropium administered by Respimat® in adolescent asthma patientsEur Resp J201750S61:PA585
   Web of Science ®Google Scholar
• US Food and Drug AdministrationTiotropium bromide clinical pharmacology review2016 Available from: https://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm549091.pdfAccessed August 30, 2017
   Google Scholar
• Boehringer Ingelheim LimitedSpiriva Respimat 2.5 microgram, inhalation solution – Summary of Product Characteristics2017
   Google Scholar
• ParkHWYangMSParkCSAdditive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict responseAllergy200964577878319183167
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineA phase III parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination (FDC) of fluticasone furoate+umeclidinium bromide+vilanterol (FF/UMEC/VI) with the FDC of FF/VI in subjects with inadequately controlled asthma Available from: https://clinicaltrials.gov/ct2/show/NCT02924688NLM identifier: NCT02924688Accessed August 30, 2017
   Google Scholar
• YangSGoyalNBeeraheeMTrivediRLeeLPascoeSDose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthmaEur J Clin Pharmacol20157191051105826174114
   PubMed Web of Science ®Google Scholar
• LeeLAYangSKerwinETrivediREdwardsLDPascoeSThe effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging studyRespir Med20151091546225452139
   PubMed Web of Science ®Google Scholar
• Pearl Therapeutics, IncChronic dosing cross-over study to assess the efficacy and safety of glycopyrronium (PT001) in adult subjects with intermittent asthma or mild to moderate persistent asthma Available from: https://clinicaltrials.gov/ct2/show/results/NCT02433834NLM identifier: NCT02433834Accessed August 30, 2017
   Google Scholar
• Chiesi Farmaceutici S.p.A.Efficacy of LAMA added to ICS in treatment of asthma (ELITRA) Available from: https://clinicaltrials.gov/ct2/show/NCT02296411NLM identifier: NCT02296411Accessed August 30, 2017
   Google Scholar
• BlaisCMDavisBECockcroftDWDuration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmaticsRespir Med20161189610127578477
   PubMed Web of Science ®Google Scholar
• University of SaskatchewanEffect of a LAMA and a uLABA on the methacholine dose-response curve Available from: https://clinical-trials.gov/ct2/show/NCT02953041NLM identifier: NCT02953041Accessed August 30, 2017
   Google Scholar
• SalmonMLuttmannMAFoleyJJPharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseasesJ Pharmacol Exp Ther2013345226027023435542
   PubMed Web of Science ®Google Scholar
• LeeLABriggsAEdwardsLDYangSPascoeSA randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthmaRespir Med20151091637325464907
   PubMed Web of Science ®Google Scholar
• AlaghaKPalotASofalviTLong-acting muscarinic receptor antagonists for the treatment of chronic airway diseasesTher Adv Chronic Dis201452859824587893
   PubMedGoogle Scholar
• BusseWWMorganWJTaggartVTogiasAAsthma outcomes workshop: overviewJ Allergy Clin Immunol20121293 SupplS1S822386504
   PubMed Web of Science ®Google Scholar
• SpahnJClinical trial efficacy: what does it really tell you?J Allergy Clin Immunol20031125 SupplS102S10614586394
   PubMedGoogle Scholar
• StåhlECorrelation between objective measures of airway calibre and clinical symptoms in asthma: a systematic review of clinical studiesRespir Med200094873574110955747
   PubMed Web of Science ®Google Scholar
• YawnBPBrennemanSKAllen-RameyFCCabanaMDMarksonLEAssessment of asthma severity and asthma control in childrenPediatrics2006118132232916818581
   PubMed Web of Science ®Google Scholar
• CrenesseDBerliozMBourrierTAlbertiniMSpirometry in children aged 3 to 5 years: reliability of forced expiratory maneuversPediatr Pulmonol2001321566111416877
   PubMed Web of Science ®Google Scholar
• FonsecaACFonsecaMTRodriguesMELasmarLMCamargosPAPeak expiratory flow monitoring in asthmatic childrenJ Pediatr (Rio J)200682646546917171206
   PubMedGoogle Scholar
• SelfTHGeorgeCMWallaceJLPattersonSJFinchCKIncorrect use of peak flow meters: are you observing your patients?J Asthma201451656657224720711
   PubMed Web of Science ®Google Scholar
• SzeflerSJChmielJFFitzpatrickAMAsthma across the ages: knowledge gaps in childhood asthmaJ Allergy Clin Immunol20141331313 quiz 1424290281
   PubMed Web of Science ®Google Scholar
• O’BrianALLemanskeRFJrEvansMDGangnonREGernJEJacksonDJRecurrent severe exacerbations in early life and reduced lung function at school ageJ Allergy Clin Immunol201212941162116422236729
   PubMed Web of Science ®Google Scholar
• O’ByrnePMPedersenSLammCJTanWCBusseWWSTART Investigators GroupSevere exacerbations and decline in lung function in asthmaAm J Respir Crit Care Med20091791192418990678
   PubMed Web of Science ®Google Scholar
• CabanaMDKunselmanSJNyenhuisSMWechslerMEResearching asthma across the ages: insights from the National Heart, Lung, and Blood Institute’s Asthma NetworkJ Allergy Clin Immunol20141331273324369796
   PubMed Web of Science ®Google Scholar
• FuhlbriggeAPedenDApterAJAsthma outcomes: exacerbationsJ Allergy Clin Immunol20121293 SupplS34S4822386508
   PubMed Web of Science ®Google Scholar
• CaldwellPHMurphySBButowPNCraigJCClinical trials in childrenLancet2004364943680381115337409
   PubMed Web of Science ®Google Scholar
• CloutierMMSchatzMCastroMAsthma outcomes: composite scores of asthma controlJ Allergy Clin Immunol20121293 SupplS24S3322386507
   PubMed Web of Science ®Google Scholar
• BacharierLBGuilbertTWDiagnosis and management of early asthma in preschool-aged childrenJ Allergy Clin Immunol20121302287296 quiz 297–29822664162
   PubMed Web of Science ®Google Scholar
• MurphyKRZeigerRSKosinskiMTest for respiratory and asthma control in kids (TRACK): a caregiver-completed questionnaire for preschool-aged childrenJ Allergy Clin Immunol20091234833.e9839.e919348922
   PubMed Web of Science ®Google Scholar
• LipworthBTargeting the small airways asthma phenotype: if we can reach it, should we treat it?Ann Allergy Asthma Immunol2013110423323923535085
   PubMed Web of Science ®Google Scholar
• CiprandiGCirilloIPasottiFRicciardoloFLFEF25-75: a marker for small airways and asthma controlAnn Allergy Asthma Immunol2013111323323987209
   PubMed Web of Science ®Google Scholar
• GibbEKaplanDThyneSMLyNPFef 25-75 as a predictor of asthma severity in childrenPaper presented at: American Thoracic Society International ConferenceMay 21; 2012San Francisco, CA
   Google Scholar
• QuanjerPHWeinerDJPrettoJJBrazzaleDJBorosPWMeasurement of FEF25–75% and FEF75% does not contribute to clinical decision makingEur Respir J20144341051105824072211
   PubMed Web of Science ®Google Scholar
• KomarowHDMylesIAUzzamanAMetcalfeDDImpulse oscillometry in the evaluation of diseases of the airways in childrenAnn Allergy Asthma Immunol2011106319119921354020
   PubMed Web of Science ®Google Scholar
• LarsenGLMorganWHeldtGPChildhood Asthma Research and Education Network of the National Heart, Lung, and Blood InstituteImpulse oscillometry versus spirometry in a long-term study of controller therapy for pediatric asthmaJ Allergy Clin Immunol20091234861.e1867.e119070356
   PubMed Web of Science ®Google Scholar
• JamesAHedlinGBiomarkers for the phenotyping and monitoring of asthma in childrenCurr Treat Options Allergy20163443945227942431
   PubMedGoogle Scholar
• McQuaidELKopelSJKleinRBFritzGKMedication adherence in pediatric asthma: reasoning, responsibility, and behaviorJ Pediatr Psychol200328532333312808009
   PubMed Web of Science ®Google Scholar
• Palo Alto Medical FoundationInhaled medications: anticholinergics2015 Available from: http://www.pamf.org/asthma/medications/inhaled/atrovent.htmlAccessed August 30, 2017
   Google Scholar
• DalbyRNEicherJZierenbergBDevelopment of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disordersMed Devices (Auckl)2011414515522915941
   PubMedGoogle Scholar
• WachtelHKattenbeckSDunneSThe Respimat® development story: Patient-centered innovationPulm Ther2017311930
   Google Scholar
• HodderRReesePRSlatonTAsthma patients prefer Respimat Soft Mist Inhaler to TurbuhalerInt J Chron Obstruct Pulmon Dis2009422523219554196
   PubMedGoogle Scholar
• Boehringer IngelheimAsthma: Expanded indication for SPIRIVA Respimat for people 6 years and older Available at: https://www.boehringer-ingelheim.com/press-release/expanded-asthma-indication-spiriva-respimat-euAccessed May 24, 2018
   Google Scholar